Belzutifan + Pembrolizumab for Clear Cell RCC
- The combination of belzutifan and pembrolizumab has been approved as adjuvant therapy for adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following surgery — the first approval of belzutifan for earlier-stage kidney cancer.
- Based on the LITESPARK-022 trial of 1,800+ patients, the combination reduced the risk of cancer recurrence, spread, or death by 28% compared to pembrolizumab alone, with 81% of combination-treated patients remaining cancer-free at two years versus 74% on standard treatment.
- Pembrolizumab boosts the immune system’s ability to attack cancer cells, while belzutifan blocks a protein critical to tumor growth. Patients should be monitored for key side effects — including anemia and low blood oxygen from belzutifan, and immune-related reactions from pembrolizumab.
The FDA has approved the combination of belzutifan and pembrolizumab for the adjuvant treatment of adult patients with clear cell RCC at intermediate-high or high risk of recurrence following nephrectomy, including patients with metastatic disease who have undergone complete resection and have no evidence of disease. The approval, announced in June 2026, is based on findings from the phase 3 LITESPARK-022 trial and introduces the first HIF2α inhibitor into the adjuvant RCC setting.
“I think this approval is important because it expands treatment options for patients with high-risk clear cell renal cell carcinoma following surgery,” Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UHospitals/Seidman Cancer Center, tells SurvivorNet Connect.
“While the results demonstrate an improvement in disease-free survival, the overall survival data remain immature, which will be an important consideration for clinicians and patients when discussing adjuvant treatment decisions,” Dr. Barata adds.
What Does the Data Say?
LITESPARK-022 was a randomized, double-blind, placebo-controlled phase 3 study that enrolled 1,836 patients with ccRCC at increased risk of recurrence following surgery. Patients were randomized to receive pembrolizumab plus belzutifan or pembrolizumab plus placebo.
The study met its primary endpoint of disease-free survival.
- The addition of belzutifan reduced the risk of recurrence, progression, or death by 28% compared with pembrolizumab alone (HR, 0.72).
- At 24 months, DFS rates were approximately 81% in the belzutifan-pembrolizumab arm versus 74% in the pembrolizumab-alone arm.
- Overall survival data remain immature at the time of approval.
“The study leading to this new approval, LITESPARK-022, randomized patients … to get about 1 year of pembrolizumab with either placebo or belzutifan. Pembrolizumab is a strong benchmark,” Dr. Michael Harrison, a medical oncologist with Duke Cancer Institute, tells SurvivorNet Connect.
“The combination reduced the risk of recurrence of cancer or death by about one-quarter. Although it is too early to tell for sure if patients on the combination may also live longer, the data are trending in that direction,” he adds.
Pembrolizumab monotherapy, established through the KEYNOTE-564 trial, has remained the standard adjuvant systemic therapy for patients with high-risk clear cell RCC following nephrectomy. The addition of belzutifan represents the first successful strategy to improve outcomes beyond adjuvant checkpoint inhibition alone.
Belzutifan has previously demonstrated efficacy in advanced RCC and VHL disease-associated tumors, but this approval marks its first use in the curative-intent adjuvant setting. The findings further validate this as a clinically meaningful therapeutic strategy across multiple stages of RCC management. The safety profile of the combination was generally consistent with the known toxicities. Belzutifan-associated adverse events include anemia and hypoxia, both on-target effects requiring routine monitoring. Pembrolizumab immune-mediated toxicities remain important management considerations.
“Belzutifan, a HIF inhibitor, in combination with Pembrolizumab, was shown to decrease the risk of recurrence when offered for a year to high-risk patients after radical nephrectomy,” Dr. Alexandria Drakaki, a medical oncologist at UCLA, tells SurvivorNet.
What the Approval Means for Practice
The approval of belzutifan plus pembrolizumab establishes a new adjuvant treatment option for patients with high-risk clear cell RCC following surgical resection. The magnitude of DFS benefit observed in LITESPARK-022 suggests that dual targeting of immune surveillance and hypoxia signaling may further reduce recurrence risk beyond that achieved with pembrolizumab alone.
Several questions remain, including the durability of the DFS benefit, the impact on overall survival, and the identification of patient subgroups most likely to derive benefit from combination therapy. Nevertheless, the approval represents a significant advance in the adjuvant management of clear cell RCC and is expected to influence treatment discussions for patients at elevated risk of recurrence after nephrectomy.
“Overall, the new approval of belzutifan will give patients and their physicians an important new tool to add to pembrolizumab with the goal of reducing the risk of kidney cancer recurrence after surgery,” Dr. Harrison says
